September 20, 2019 11:31 AM EDT
News Briefing

Astel­las/Fi­bro­Gen's ane­mia drug for CKD pa­tients ap­proved in Japan; Re­searchers pro­pose com­bo to stay ahead of KRAS re­sis­tance

Jason Mast

Editor

→ Rox­adust, a treat­ment for ane­mia that aris­es as a com­pli­ca­tion in chron­ic kid­ney dis­ease, has been ap­proved in Japan. De­vel­oped by Fi­bro­Gen and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er wants in on Sum­mit’s goal to beat Keytru­da via ADC com­bos

Post-Hoc: Phar­ma CEOs' al­ter­na­tive re­al­i­ty with Trump

Sanofi, Te­va bol­ster case for IBD drug with Phase 2 da­ta, de­spite po­ten­tial com­pe­ti­tion

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times